A fascinating frontier in early 2026 oncology is the focus on the "Tumor Microenvironment" and the role of the human microbiome in drug efficacy. Scientists have discovered that the success of a PD-L1 inhibitor is often determined by the health of the patient's gut bacteria, which acts as a "training ground" for the immune system. In early 2026, many leading oncology centers now prescribe...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
English
French
Spanish
Italiano
Romaian
Portuguese (Brazil)
china